Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 14 | ECE2007 | Next issue

9th European Congress of Endocrinology

Oral Communications

Neuroendocrinology clinical

ea0014oc8.1 | Neuroendocrinology clinical | ECE2007

Growth hormone response during OGTT: the impact of assay method, gender and BMI on the estimation of reference values in patients with acromegaly and in healthy controls

Arafat Ayman M , Möhlig Mathias , Weickert Martin O , Perschel Frank H , Purschwitz Johannes , Spranger Joachim , Strasburger Christian J , Schöfl Christof , Pfeiffer Andreas FH

Objectives: Besides the measurement of IGF-1, GH suppression during OGTT to assess the biochemical status in acromegaly is recommended. However, as a consequence of the development of highly sensitive and specific GH assays a critical re-evaluation of the criteria for the diagnosis and follow-up management of acromegaly is mandatory. The aim of our study was to evaluate the between-method discrepancies in GH determinations by different immunoassays considering further confound...

ea0014oc8.2 | Neuroendocrinology clinical | ECE2007

Effect of GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in acromegalic patients resistant to somatostatin analogues

De Martino Maria Cristina , Auriemma Renata S , Brevetti Gregorio , Galdiero Mariano , De Leo Monica , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Acromegaly is known to be associated to an increased cardiovascular risk, due to the increased prevalence of glucose intolerance and dyslipidemia and pre-atherosclerotic lesions. The aim of this study was to evaluate the effect of treatment with the GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in patients with acromegaly resistant to somatostatin analogues. Twelve patients (4 m, 8 f, 28–58 yrs) and 24 sex-, age- and BMI-matched controls en...

ea0014oc8.3 | Neuroendocrinology clinical | ECE2007

Pituitary imaging abnormalities in patients with and without hypopituitarism after traumatic brain injury

Schneider Harald J. , Croce Chiara G. , Corneli Ginevra , Ghigo Ezio , Stalla Günter K. , Aimaretti Gianluca

Recent evidence shows that patients with traumatic brain injury (TBI) are at substantial risk of hypopituitarism. However, the pathomechanisms are still not completely understood. Little is known about the association of morphological changes in the sella region with pituitary function in TBI. In this study, we assessed morphological abormalities of the sella region in patients with TBI and their relation to endocrine function.We have studied MR or CT sc...

ea0014oc8.4 | Neuroendocrinology clinical | ECE2007

Idiopathic central hypothyroidism: report of a human natural model of congenital TRH receptor (TRHR) absence

Bonomi Marco , Busnelli Marta , Pilotta Alba , Prandi Elena , Maggi Mario , Buzi Fabio , Beck-Peccoz Paolo , Persani Luca

Central Hypothyroidism (CeH) is a rare thyroid hormone production defect due to an insufficient stimulation of a normal thyroid gland. Candidate genes for isolated CeH include TSHβ (several cases reported) and TRHR (only one case reported so far). Here, we report the clinical and genetic studies in 2 males and 3 females affected with isolated CeH with normal/low TSH levels (0.05–0.95 mU/L) and low FT4 levels (3.6–4.6 pM). None of the patients was detected at neo...

ea0014oc8.5 | Neuroendocrinology clinical | ECE2007

Inoperable pituitary tumours treated with 90Y-DOTA-TATE – initial results

Kaminski Grzegorz , Szalus Norbert , Zielinski Grzegorz , Podgajny Zbigniew , Zgliczynski Wojciech , Kasperlik-Zaluska Anna , Cyperling-Kaminska Joanna , Dziuk Eugeniusz

Introduction: The patients with inoperable hormone - secreting pituitary tumours are treated with cold somatostatin analogues, but it is not always effective. DOTA-TATE preparation is a somatostatin analogue coupled with β (−) emitter 90 Y. The efficacy of the treatment is based on excessive expression of somatostatin receptors (SSTR) in these tumours.The aim of the study: To assess the feasibility of treatment of pituitary tumours ...

ea0014oc8.6 | Neuroendocrinology clinical | ECE2007

Improved glucocorticoid replacement therapy by a novel oral hydrocortisone modified-release tablet

Skrtic Stanko , Lennernäs Hans , Nilsson Anna , Bergthorsdottir Ragnhildur , Hedner Thomas , Johannsson Gudmundur

Background: Mortality rate in patients with primary and secondary adrenal insufficiency is increased. A contributing factor could be the dose and the pattern of glucocorticoid replacement therapy. Hydrocortisone administered twice or thrice daily produces high serum peaks and low trough values in-between. A novel, once daily, hydrocortisone modified release tablet with combined immediate and extended release characteristics was developed.Purpose: The aim...

ea0014oc8.7 | Neuroendocrinology clinical | ECE2007

A single intravenous bolus of dexamethasone for the diagnosis of Cushing’s syndrome

Munter Gabriel , Kirshner Moriah , Ariel Rosler , Shmuel Shilo , Gil Leibowitz , Benjamin Glaser

The diagnosis of Cushing’s syndrome (CS) is based primarily on diagnostic tests evaluating the cortisol response to dexamethasone suppression. Tests based on oral administration of dexamethasone may be compromised by poor compliance. We evaluated the diagnostic accuracy of a novel intravenous dexamethasone suppression test (IDST). The test is performed by intravenous (iv) bolus injection of 8 mg dexamethasone, with blood cortisol determinations made before injection, then...